Phase II drug metabolism and individualized drug therapy: A focus on functional genetic variation in UDP-glucuronosyltransferases

Current Pharmacogenomics and Personalized Medicine

Volumn 8, Issue 2, 2010, Pages 146-166

  Maruo, Yoshihiro ^a   Takahashi, Hiroko ^a   Matsui, Katusyuki ^a   Sato, Hiroshi ^a   Takeuchi, Yoshihiro ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Drug metabolism; Functional polymorphism; Genetic variation; Glucuronidation capacity; Personalized medicine; Phase II metabolism; UDP glucuronosyltransferase; UGTs

Indexed keywords

4 NITROPHENOL; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANDROSTERONE; ANTHRAQUINONE DERIVATIVE; BENZIDINE; BUPRENORPHINE; CLOZAPINE; CYPROHEPTADINE; ESTRADIOL; ESTRIOL; ESTROGEN DERIVATIVE; FLAVONOID; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A5; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2; IBUPROFEN; IMIPRAMINE; LOSARTAN; MESSENGER RNA; NALTREXONE; UMBELLIFERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME SUBSTRATE; GENE EXPRESSION; GENE MUTATION; GENE STRUCTURE; GENETIC VARIABILITY; HUMAN; PHARMACEUTICAL CARE; PSEUDOGENE; TISSUE DISTRIBUTION;

EID: 77953739577     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569210791383901     Document Type: Article

References (144)

1. Mackenzie PI, Owens IS, Burchell B, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7(4): 255-69.
2. Maruo Y, Iwai M, Mori A, et al. Polymorphism of UDP-glucuronosyltransferase and drug metabolism. Curr Drug Metab 2005; 6(2): 91-9.
3. Nagar S, Remmel RP. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 2006; 25(11): 1659-72.
4. Ritter JK, Chen F, Sheen YY, et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 267; 1992: 3257-61.
5. Gong QH, Cho JW, Huang T, et al. Thirteen UDP glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001; 11(4): 357-68.
6. King CD, Rios MD, Green MD, et al. UDP-glucuronosyltransferases. Curr Drug Metab 2000; 1(2): 143-61.
7. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333(18): 1171-5.
8. Lévesque E, Turgeon D, Carrier JS, et al. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry 2001; 40(13): 3869-81.
9. Jedlitschiky G, Cassidy AJ, Sales M, et al. Cloning and characterization of a novel human olfactory UDP-glucuronosyltransferase. Biochem J 1999; 340(Pt3): 837-3.
10. Ritter JK, Chen F, Sheen YY, et al. Two human liver cDNAs encode UDP-glucuronosyltransferases with 2 log differences in activity toward parallel substrates including hyodeoxycholic acid and certain estrogen derivatives. Biochemistry 1992; 31(13): 2409-14.
11. Jin C, Miners JO, Lillywhite KJ, et al. cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun 1993; 194(1): 496-503.
12. Lévesque E, Beaulieu M, Green MD, et al. Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997; 7(4): 317-25.
13. Lévesque E, Beaulieu M, Hum DW, et al. Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1999; 9(2): 207-16.
14. Murata, M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003; 197(10): 1279-89.
15. Chen G, Blevins-Primeau AS, Dellinger RW, et al. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. Cancer Res 2007; 67(19): 9024-9.
16. Ritter JK, Crawford KM, Owens IS. Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. J Biol Chem 1991; 266(2): 1043-7.
17. Ito M, Yamamoto K, Maruo Y, et al. Effect of a conserved mutation in uridine diphosphate glucuronosyltransferase 1A1 and 1A6 on glucuronidation of a metabolite of flutamide. Eur J Pharmacol 2002; 58(1): 11-4.
18. Senfi SB, Clarke DJ, Burchell B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 1994; 303(1): 233-40.
19. King CD, Green MD, Rois GR, et al. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys 1996; 332(1): 92-100.
20. Bosma PJ, Seppen J, Goldhoorn B, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 1994; 269(27): 17960-4.
21. Adachi Y, Kamisako T, Koiwai O, et al. Genetic background of constitutional unconjugated hyperbilirubinemia. Int Hepatol Commun 1996; 5: 297-307.
22. Kadakol A, Ghosh SS, Sappal BS, et al. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2001; 16(4): 297-306.
23. Owens D, Evans J. Population studies on Gilbert's syndrome. J Med Gene 1975; 12(2): 152-6.
24. Bailey A, Robinson D, Dawson AM. Does Gilbert's disease exist? Lancet 1977; 30(1): 931-3.
25. Servedio V, d'Apoltio M, Mariorano N, et al. Spectrum of UGT1A1 mutations in Cgler-Najjar (CN) syndrome patients: identification of twelve novel alleles and genotype-phenotype correlation. Hum Mutat 2005; 25(3): 325.
26. D'Apolito M, Marrone A, Servedio V, et al. Seven novel mutations of the UGT1A1 gene in patients with unconjugated hyperbilirubinemia. Haematologica 2007; 92(1): 133-4.
27. Maruo Y, Serdaroglu E, Iwai M, et al. A novel missense mutation of the bilirubin UDP-glucuronosyltransferase gene in a Turkish patient with Crigler-Najjar syndrome type 1. J Pediat Gastroenterol Nutr 2003; 37(5): 627-630.
28. Maruo Y, Verma IC, Matsui K, et al. Conformational change of UGT1A1 by a novel missense mutation (p.L131P) causing Crigler-Najjar syndrome type I. J Pediatr Gastroenterol Nutr 2008; 46(3): 308-11.
29. Aono S, Yamada Y, Keino H, et al. Identification of defect in the genes for bilirubin UDP-glucuronosyltransferase in a patient with Crigler-Najjar syndrome type II. Biochem Biophys Res Commun 1993; 197(3): 1239-44.
30. Maruo Y, Topaloglu AK, Takahashi H, et al. Crigler-Najjar syndrome type II caused by a homozygous triple mutation. [T-3279G, A(TA)7TAA, and H39D] of UGT1A1. J Pediatr Gastroenterol Nutr 2006; 42(2): 236-9.
31. Yamamoto K, Sato H, Fujiyama Y, et al. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyl transferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim Biophys Acta 1998; 1406(3): 267-73.
32. Maruo Y, Sato H, Yamano T, et al. Gilbert syndrome caused by a homozygous missense mutation (Tyr486Asp) of bilirubin UDP-glucuronosyltransferase gene. J Pediatr 1998; 132(6): 1045-7.
33. Maruo Y, Wada S, Yamamoto K, et al. A case of anorexia nervosa with hyperbilirubinaemia in a patient homozygous for a mutation in the bilirubin UDP-glucuronosyltransferase gene. Eur J Pediatr 1998; 158(7): 547-9.
34. Sugatani J, Yamakawa K, Yoshinari K, et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia: Biochem Biophys Res Commun 2002; 292(2): 492-7.
35. Monaghan G, Ryan M, Seddon R, et al. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347(9001): 578-81.
36. Mackenzie PI, Bock KW, Burchell B, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005; 15(10): 677-85.
37. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95(14): 8170-4.
38. Ueyama H, Koiwai O, Soeda Y, et al. Analysis of the promoter of human bilirubin UDP-glucuronosyltransferase gene (UGT1*1) in relevance to Gilbert's syndrome. Hepatol Res 1997; 9: 152-63.
39. Maruo Y, Nishizawa K, Sato H, et al. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics 1999; 103(6): 1224-7.
40. Sugatani J, Kojima H, Ueda A, et al. The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyl transferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 2001; 33(5): 1232-8.
41. Innocenti F, Grimsley C, Das S, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12(9): 725-33.
42. Kaniwa N, Kurose K, Jinno H, et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab Dispos 2005; 33(3): 458-65.
43. Maruo Y, D'Addario C, Mori A, et al. Two linked polymorphic mutations (A(TA)7TAA and T-3279G) of UGT1A1 as the principal cause of Gilbert syndrome. Hum Genet 2004; 115(6): 525-6.
44. Akaba K, Kimura T, Sakai A, et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyl transferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 1998; 46(1): 21-6.
45. Sato H, Adachi Y, Koiwai O. The genetic basis of Gilbert's syndrome. Lancet 1996; 347(9001): 557-8.
46. Newman MD, Easterling MJ, Goldman ES, et al. Laboratory evaluation of jaundice in newborns. Frequency, cost, and yield. Am J Dis Child 1990; 146(2): 1420-1.
47. Maruo Y, Nishizawa K, Sato H, et al. Prolonged unconjugated hyperbilirubinemia associated with breast milk and mutations of the bilirubin uridine diphosphate glucuronosyltransferase gene. Pediatrics 2000; 106(5); e59.
48. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101(4): 947-54.
49. Gagne JF, Montminy V, Belanger P, et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62(3): 608-17.
50. Ciotti M, Basu N, Brangi M, et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyl transferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999; 260(1): 199-202.
51. Hanioka N, Ozawa S, Jinno H, et al. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 2001; 31(10): 687-99.
52. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65(5): 576-82.
53. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60(24): 6921-6.
54. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11(3): 1226-36.
55. Guillemette C, Millikan RC, Newman B, et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000; 60(4): 950-6.
56. Takekuma Y, Takenaka T, Kiyokawa M, et al. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. J Pharm Pharm Sci 2006; 9(1): 101-12.
57. Maruo Y, Sato H, Bamba N, et al. Chemotherapy-induced unconjugated hyperbilirubinemia caused by a mutation of the bilirubin uridine-5'-diphosphate-glucuronosyltransferase gene. J Pediatr Hematol Oncol 2001; 23(1): 45-7.
58. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001; 98(22): 12671-6.
59. Iwai M, Maruo Y, Ito, M, et al. Six novel UDP-glucuronosyl transferase (UGT1A3) polymorphisms with varying activity. J Hum Genet 2004; 49(3): 123-8.
60. Ehmer U, Vogel A, Schutte JK, et al. Variation of hepatic glucuronidation: novel functional polymorphisms of the UDPglucuronosyltransferase UGT1A4. Hepatology 2004; 39(4): 970-7.
61. Caillier B, Lépine J, Tojcic J, et al. A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3. Pharmacogenet Genomics 2007; 17(7): 481-95.
62. Mori A, Maruo Y, Iwai M, et al. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos 2005; 33(5): 672-5.
63. Saeki M, Saito Y, Jinno H, et al. Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 2005; 20(1): 144-51.
64. Sun D, Chen G, Dellinger RW, et al. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 2006; 8(4): R50.
65. Wiener D, Fang JL, Dossett N, et al. Correlation between UDPglucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res 2004; 64(3); 1190-6.
66. Finel M, Li X, Gardner-Stephen D, et al. Human UDPglucuronosyltransferase 1A5: identification, expression, and activity. J Pharmacol Exp Ther 2005; 315: 1143-9.
67. Falany CN, Tephly TR. Separation, purification and characterization of three isoenzymes of UDP-glucuronosyltransferase from rat liver microsomes. Arch Biochem Biophys 1983; 227(1): 248-58.
68. Münzel PA, Bookjans G, Mehner G, et al. Tissue-specific 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible expression of human UDPglucuronosyltransferase UGT1A6. Arch Biochem Biophys 1996: 335(1): 205-10.
69. Bock KW, Forster A, Gschaidmeier H, et al. Paracetamol glucuronidation by recombinant rat and human phenol UDPglucuronosyltransferases. Biochem Pharmacol 1993; 45(9): 1809-14.
70. Ebner T, Burchell B. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 1993; 21(1): 50-5.
71. Martinasevic MK, King CD, Rios GR, et al. Immunohistochemical localization of UDP-glucuronosyltransferases in rat brain during early development. Drug Metab Dispos 1998; 26(10): 1039-41.
72. King CD, Rios CR, Assouline JA, et al. Expression of UDPglucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. Arch Biochem Biophys 1999; 365(1): 156-62.
73. Ciotti M, Marrone A, Potter C, et al. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 1997; 7(6): 485-95.
74. Nagar S, Zalatoris JJ, Blanchard RL. Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 2004: 14(8): 487-99.
75. Saeki M, Saito Y, Jinno H, et al. Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab Pharmacokinet 2005; 20(9): 85-90.
76. Bigler J, Whitton J, Lampe JW, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001; 61(9): 3566-9.
77. Chan AT, Tranah GJ, Giovannucci EL, et al. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst 2005; 97(6): 457-60.
78. Tankanitlert J, Morales NP, Howard TA, et al. Effects of combined UDP-glucuronosyltransferase (UGT) 1A1*28 and 1A6*2 on paracetamol pharmacokinetics in beta-thalassemia/HbE. Pharmacology 2007; 79(2): 97-103.
79. Strassburg CP, Oldhafer K, Manns MP, et al. Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 1997; 52(2): 212-20.
80. Strassburg CP, Manns MP, Tephly RH. Expression of the UDPglucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 1998; 273(15): 8719-26.
81. Strassburg CP, Strassburg A, Neuyen N, et al. Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Biochem J 1999; 338: 489-98.
82. Kobayashi T, Yokota H, Ohgiya S, et al. UDP-glucuronosyltransferase UGT1A7 induced in rat small intestinal mucosa by oral administration of 2-naphthoflavone. Eur J Biochem 1998; 258(3): 948-55.
83. Grove AD, Kessler FK, Metz BP, et al. Identification of a rat oltipraz inducible UDP-glucuronosyltransferase (UGT1A7) with activity towards benzo(a)pyrene-7,8-dihydrodiol. J Biol Chem 1997; 272(3): 1621-7.
84. Guillemette C, Ritter JK, Auyeyng DJ, et al. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000; 10(7): 629-44.
85. Villeneuve L, Girard H, Fortier LC, et al. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 2003; 307(1): 117-28.
86. Fujita K, Ando Y, Nagashima F, et al. Novel single nucleotide polymorphism of UGT1A7 gene in Japanese. Drug Metab Pharmacokinet 2006; 21(1): 75-8.
87. Chen K, Jin M, Zhu Y, et al. Genetic polymorphisms of the uridine diphosphate glucuronosyltransferase 1A7 and colorectal cancer risk in relation to cigarette smoking and alcohol drinking in a Chinese population. J Gastroenterol Hepatol 2006; 21(6): 1036-41.
88. Strassburg CP, Vogel A, Kneip S, et al. Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 2000; 50(6): 851-6.
89. Vogel A, Kneip S, Barut A, et al. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 2001; 12(5): 1136-44.
90. Chen Z, Radominska-Pandya A, Tephly TR. Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8. Arch Biochem Biophys 1998; 356(2): 301-5.
91. Cheng Z, Radominska-Pandya A, Tephly TR. Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab Disps 1999; 27(10): 1165-70.
92. Huang YH, Galijatovic A, Nguyen N, et al. Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics 2002; 12(4): 287-97.
93. Saeki M, Saito Y, Jinno H, et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 2006; 6(1): 63-75.
94. Bernard O, Tojcic J, Journault K, et al. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos 2006; 34(9): 1539-45.
95. Wooster R, Sutherland L, Ebner T, et al. Cloning and stable expression of a new member of the human liver phenol/ bilirubin:UDP-glucuronosyltransferase cDNA family. Biochem J 1991; 278(2): 465-9.
96. Paoluzzi L, Singh AS, Price DK, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 2004; 44(8): 854-60.
97. Fujita K, Ando Y, Nagashima F, et al. Novel single nucleotide polymorphism of UGT1A9 gene in Japanese. Drug Metab Pharmacokinet 2006; 21(1): 79-81.
98. Jinno H, Saeki M, Saito Y, et al. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 2003; 306(2): 688-93.
99. Mehlotra RK, Bockarie MJ, Zimmerman PA. Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations. Eur J Clin Pharmacol 2007; 63(1): 1-8.
100. Thibaudeau J, Lepine J, Tojcic J, et al. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactive mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 2006; 66(1): 125-33.
101. Girard H, Court MH, Bernard O, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14(8): 501-15.
102. Yamanaka H, Nakajima M, Katoh M, et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004; 14(5): 329-32.
103. Takahashi H, Maruo Y, Mori A, et al. Effect of D256N and Y483D on propofol glucuronidation by human UDP-glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol 2008; 103(2): 131-6.
104. Mojarrabi B, Mackenzie PI. The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid. Biochem Biophys Res Commun 1997; 238(3): 775-8.
105. Mojarrabi B, Mackenzie PI. Characterization of two UDP glucuronosyltransferases that are predominantly expressed in human colon. Biochem Biophys Res Commun 1998; 247(3): 704-9.
106. Saeki M, Ozawa S, Saito Y, et al. Three novel single nucleotide polymorphisms in UGT1A10. Drug Metab Pharmacokin 2002; 17(5): 488-90.
107. Jinno H, Saeki M, Kagawa TT, et al. Functional characterization of wild-type and variant (T202I and M59I) human UDPglucuronosyltransferase 1A10. Drug Metab Dispos 2003; 31(5): 528-32.
108. Elahi A, Bendaly J, Zheng Z, et al. Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 2003; 98(4): 872-80.
109. Dellinger RW, Fang JL, Chen G, et al. Importance of UDPglucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos 2006; 34(6): 943-9.
110. Kato S, Hiura H, Kisaki O, et al. Gene frequencies of G71R, TA(TA)7TAA and Y486D of UDP-glucuronosyltransferase (UGT1A1). Rinsho Byori 2006; 54(Suppl.): 151.
111. Jinno H, Tanaka-Kagawa T, Hanioka N, et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 2003; 31(1): 108-13.
112. Kurkela M, Hirvonen J, Kostiainen R, et al. The interactions between the N-terminal and C-terminal domains of the human UDP-glucuronosyltransferases are partly isoform-specific, and may involve both monomers. Biochem Pharmacol 2004; 68(12): 2443-50.
113. Kraemer D, Klinker H. Crigler-Najjar syndrome type II in a Caucasian patient resulting from two mutations in the bilirubin uridine 5'-diphosphate-glucuronosyltransferase (UGT1A1) gene. J Hepatol 2002; 36(5): 706-7.
114. Lazard D, Zupko K, Poria Y, et al. Odorant signal termination by olfactory UDP glucuronosyltransferase. Nature 1991; 349(6312): 790-3.
115. Iida A, Saito S, Sekine A, et al. Catalog of 86 single-nucleotide polymorphisms (SNPs) in three uridine diphosphate glycosyltransferase genes: UGT2A1, UGT2B15, and UGT8. J Hum Genet 2002; 47(10): 505-10.
116. Jin C, Miners JO, Lillywhite KJ, et al. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 1993; 264(1): 475-9.
117. Lampe JW, Bigler J, Bush AC, et al. Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4 (D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol Biomark Prev 2000; 9(3): 329-33.
118. Saeki M, Saito Y, Jinno H, et al. Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos 2004; 32(9): 1048-54.
119. Sparks R, Ulrich CM, Bigler J, et al. UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res 2004; 6(5): R488-98.
120. Ritter JK, Sheen YY, Owens IS. Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. 3,4-catechol estrogens and estriol as primary substrates. J Biol Chem 1990; 265(12): 7900-6.
121. Terrier N, Benoit E, Senay C, et al. Human and rat liver UDPglucuronosyltransferases are targets of ketoprofen acylglucuronide. Mol Pharmacol 1999; 56(1): 226-34.
122. Coffman BL, Rios GR, King CD, et al. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997; 25(1): 1-4.
123. Bhasker CR, McKinnon W, Stone A, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10(8): 679-85.
124. Hirota T, Ieiri I, Takan H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 2003; 31(5): 677-80.
125. Coffman BL, King CD, Rios GR, et al. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998; 26(1): 73-7.
126. Innocenti F, Liu W, Fackenthal D, et al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics 2008; 18(8): 683-97.
127. Lévesque E, Delage R, Beniot-Biancamano MO, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Therap 2007; 81(3): 392-400.
128. Lin GF, Guo WC, Chen JG, et al. An association of UDPglucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol Sci 2005; 85(1): 502-6.
129. Swanson C, Lorentzon M, Vandenput L, et al. Sex steroid levels and cortical bone size in young men are associated with a uridine diphosphate glucuronosyltransferase 2B7 polymorphism (H268Y). J Clin Endocrinol Metab 2007; 92(9): 3697-704.
130. Beaulieu M, Lévesque E, Hum DW, et al. Isolation and characterization of a human orphan UDP-glucuronosyltransferase, UGT2B11. Biochem Biophys Res Commun 1998; 248(1): 44-50.
131. Turgeon D, Chouinard S, Belanger P, et al. Glucuronidation of arachidonic and linoleic acid metabolites by human UDPglucuronosyltransferases. J Lipid Res 2003; 44(6): 1182-91.
132. Kaivosaari S, Toivonen P, Hesse LM, et al. Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol Pharmacol 2007; 72(3): 761-8.
133. Chen G, Dellinger RW, Gallagher CJ, et al. Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobaccospecific nitrosamines. Pharmacogenet Genomics 2008; 18(3): 181-91.
134. Chen G, Dellinger, RW, Sun D, et al. Glucuronidation of tobaccospecific nitrosamines by UGT2B10. Drug Metab Dispos 2008; 36(5): 824-30.
135. Chen F, Ritter JK, Wang MG, et al. Characterization of a cloned human dihydrotestosterone/androstanediol UDP-glucuronosyltransferase and its comparison to other steroid isoforms. Biochemistry 1993; 32(40): 10648-57.
136. Green MD, Oturu EM, Tephly TR. Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metab Dispos 1994; 22(5): 799-805.
137. Court MH, Hao Q, Krishnaswamy S, et al. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 2004; 310(2): 656-65.
138. MacLeod SL, Nowell S, Plaxco J, et al. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 2000; 7(10): 777-82.
139. Beaulieu M, Levesque E, Hum DW, et al. Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyl transferase active on C(19) steroids. J Biol Chem 1996; 271(37): 22855-62.
140. Beaulieu M, Levesque E, Tchernof A, et al. Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme. DNA Cell Biol 1997; 16(10): 1143-54.
141. Xue Y, Sun D, Daly A, et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet 2008; 83(3): 337-46.
142. Park J, Chen L, Ratnashinge L, et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 2006; 15(8): 1473-8.
143. Terakura S, Murata M, Nishida T, et al. A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. Br J Haematol 2005; 129(2): 221-8.
144. Gallagher CJ, Kadlubar FF, Muscat JE, et al. The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians. Cancer Detect Prev 2007; 31(4): 310-5.